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Abstract
Biallelic mutations in the photoreceptor-expressed aryl hydrocarbon receptor interacting protein-like 1 (AIPL1) are associated
with autosomal recessive Leber congenital amaurosis (LCA), the most severe form of inherited retinopathy in early childhood.
AIPL1 functions as a photoreceptor-specific co-chaperone that interacts with the molecular chaperone HSP90 to facilitate the
stable assembly of the retinal cyclic GMP (cGMP) phosphodiesterase (PDE6) holoenzyme. In this study, we characterized the
functional deficits of AIPL1 variations, some of which induce aberrant pre-mRNA AIPL1 splicing leading to the production of al-
ternative AIPL1 isoforms. We investigated the ability of the AIPL1 variants to mediate an interaction with HSP90 and modulate
the rod cGMP PDE6 stability and activity. Our data revealed that both the FK506 binding protein (FKBP)-like domain and the tetra-
tricopeptide repeat (TPR) domain of AIPL1 are required for interaction with HSP90. We further demonstrate that AIPL1 signifi-
cantly modulates the catalytic activity of heterologously expressed rod PDE6. Although the N-terminal FKBP-like domain of
AIPL1 binds the farnesylated PDE6a subunit through direct interaction with the farnesyl moiety, mutations compromising the
integrity of the C-terminal TPR domain of AIPL1 also failed to modulate PDE6 activity efficiently. These AIPL1 variants moreover
failed to promote the HSP90-dependent stabilization of the PDE6a subunit in the cytosol. In summary, we have successfully vali-
dated the disease-causing status of the AIPL1 variations in vitro. Our findings provide insight into the mechanism underlying the
co-chaperone role of AIPL1 and will be critical for ensuring an early and effective diagnosis of AIPL1 LCA patients.
Introduction
Leber congenital amaurosis (LCA) is the most rapid and severe
inherited retinal degeneration that causes visual impairment in
childhood (1). Typically inherited in an autosomal recessive
manner, LCA is characterized by marked reduction or complete
loss of both rod and cone photoreceptor responses within the
first few years of life (2). To date, at least 25 genes have been
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associated with LCA (RetNet; https://sph.uth.edu/retnet), in-
cluding AIPL1, a gene comprised of six exons coding for the aryl
hydrocarbon receptor interacting protein-like 1 (3). AIPL1 muta-
tions are estimated to account for 5–10% of LCA cases (RetNet)
resulting in one of the most clinically severe forms of the dis-
ease (LCA type 4) (OMIM AIPL1; #604393) (4,5,6).
The 384 amino acid protein AIPL1, whose expression is lim-
ited to the retina and the pineal gland, shares 50% sequence iden-
tity with the ubiquitously expressed aryl hydrocarbon receptor
interacting protein AIP (3,7). Functionally, AIPL1 is similar to
FK506 binding protein (FKBP)51, FKBP52 and AIP, all of which are
members of a group of co-chaperones that interact with the mo-
lecular chaperone HSP90 via a conserved C-terminal tetratrico-
peptide repeat (TPR) domain (8–10). The AIPL1 TPR domain
consists of three TPR motifs, which are highly degenerate 34
amino acid repeats (11,12). HSP90, typically the most abundant
cytoplasmic adenosine triphosphate (ATP)-dependent molecular
chaperone in vertebrate cells, is a dynamic dimer that acts in
complex with co-chaperones on native-like protein substrates
called clients, serving a vital role in cellular signalling by regulat-
ing client folding, activity and stability (13). Each HSP90 monomer
consists of three functionally distinct domains: a N-terminal do-
main (NTD) that confers nucleotide binding, a middle domain
(MD) necessary for ATPase activity and a C-terminal domain
(CTD) responsible for constitutive dimerization (14). A highly con-
served IEEVD or MEEVD motif located at the very C-terminus of
HSP70 and HSP90, respectively, is the primary interaction site for
the TPR domain-containing co-chaperones, including AIPL1
(10,15–18). However, the affinity and specificity of the interaction
of the TPR domain co-chaperones with HSP90 may involve
charged and hydrophobic residues upstream of the HSP90
MEEVD sequence as well as contacts outside of the TPR motifs
(19–22). In addition, human AIPL1 harbours a unique primate-
specific unstructured C-terminal proline-rich domain (PRD),
which has been reported to influence the association with HSP90
in an inhibitory manner or have no effect thereupon (23,24).
Several in vivo and in vitro studies have established a link be-
tween AIPL1 and the cyclic nucleotide phosphodiesterase of the
sixth family (PDE6), a holoenzyme that catalyses the hydrolysis
of cyclic GMP (cGMP) upon light stimulation in photoreceptor
cells. Aipl1 knockout and hypomorphic murine models revealed
that in the absence of AIPL1, the PDE6 subunits are misas-
sembled and rapidly targeted for proteasomal degradation,
leading to the absence of a response to light stimuli and
triggering rapid degeneration of the rod and cone photorecep-
tors (25–29). Recently, it was reported that AIPL1 is required to
reconstitute the catalytic activity of the heterologously ex-
pressed cone PDE6 (30). The N-terminal FKBP-like domain of
AIPL1, which lacks peptidylprolyl isomerase activity (22) directly
binds a farnesyl or geranylgeranyl moiety in vitro (24,31–33) and
is therefore proposed to mediate the interaction with the farne-
sylated rod PDE6a subunit and with the geranylgeranylated rod
PDE6b and cone PDE6a’ subunits. Finally, PDE6 has been identi-
fied as an HSP90 client as inhibition of HSP90 in vivo in the retina
led to a posttranslational reduction in PDE6 levels (34).
The AIPL1 gene is highly polymorphic with more than
400 AIPL1 variations annotated in the Exome Aggregation
Consortium (ExAC) data set (exac.broadinstitute.org). We have
recently reported that missense or intronic variations in AIPL1
cause aberrant pre-mRNA splicing leading to the production of
transcripts that could encode functionally deficient protein iso-
forms (35). Although in silico prediction tools are frequently used
to ascertain the probable pathogenicity of genetic variations,
only a handful have been experimentally validated and
reported as pathogenic mutations (Human Gene Mutation
Database; http://www.hgmd.org) (31,32,36–39). In this study, we
investigated the functional impact of novel and uncharacterized
AIPL1 nonsense, missense and intronic variations to confirm
their disease-causing status and gain insight into the role of
AIPL1 as a HSP90 co-chaperone for PDE6. We investigated the
interaction of the AIPL1 variants with HSP90 and their require-
ment for the stable expression and function of rod PDE6.
Results
AIPL1 variations investigated
In this study, we engineered LCA associated non-synonymous
missense and nonsense variations as well as small insertions
and duplications in the coding sequence of the AIPL1 cDNA (Fig.
1A). The resultant amino acid changes are distributed through-
out AIPL1 including the N-terminal FKBP-like domain and the
C-terminal TPR domain (Fig. 1A and B). Intronic canonical splice
site variations, small deletions spanning a canonical splice site
and small coding insertions and duplications or missense varia-
tions in the first or last base of an exon immediately adjacent to
a canonical splice site were all recently confirmed to induce ab-
errant splicing of the AIPL1 gene (35) (Fig. 1C). We engineered
the AIPL1 protein isoforms predicted to be translated from these
alternative transcripts in the coding sequence of the AIPL1
cDNA to investigate their impact on AIPL1 function (Fig. 1C and D).
All of these AIPL1 variations completely abolished native splice
site recognition (35), except c.97_104dupGTGATCTT and
c.98_99insTGATCTTG, where native splice site recognition led to
the translation of the frameshift stopped products p.F35Lfs*2 and
p.I34Dfs*10, respectively (Fig. 1A), whilst aberrant transcription
lead to the production of p.V33Sfs*57 (Fig. 1C). The coding missense
variations c.465G>T, c.642G>C and c.784G>A also completely
abolished native splice site recognition leading to the complete
loss of transcripts coding for p.Q155H, p.K214N and p.G262S, re-
spectively, and the exclusive expression of alternative transcripts
(35) (Fig. 1C). However, in addition to engineering the expected pro-
tein isoforms expressed as a result of alternative transcription (Fig.
1C), we also engineered c.642G>C (p.K214N) and c.784G>A
(p.G262S) in the coding sequence of the AIPL1 cDNA (Fig. 1A and B)
to investigate their impact on AIPL1 function and confirm AIPL1
missplicing as the underlying cause of disease in LCA patients har-
bouring these variations. We investigated the frequency of all the
AIPL1 variations investigated in this study in the current ExAC data
set of 60 706 unrelated individuals (Supplementary Material, Table
S1). Several of the variations investigated are not identified while
the remainder are all very rare (allele frequency< 1/10 000), and
none are observed in the homozygous state. In silico analysis of the
missense variations reveals that all are predicted to be damaging,
with the exception of c.465G>T (p.Q155H) and c.784G>A
(p.G262S) which are predicted to be benign by at least one predic-
tion programme.
Premature translation termination leads to AIPL1
misfolding and aggregation
We first investigated the expression and subcellular localization
of the AIPL1 variants by western blotting and immunofluores-
cent confocal microscopy (Fig. 2). The myc tagged AIPL1 vari-
ants, p.L17P, p.G64R, p.C89R, p.V71F, p.Q163*, p.K214N and
p.E282_283dup, were all similar to wild-type (w/t) AIPL1 in their
expression (Fig. 2A and B) and subcellular distribution (Fig. 2C).
Similarly, western blotting and immunofluorescence confocal
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microscopy revealed that AIPL1 isoforms resulting from alterna-
tive transcription (p.V33_I92del, p.V33_Q155del, p.H93_Q155del,
p.V148_Q155del, p.V156_K214del, p.K214_E215insVRGRWPG,
p.V249Afs*3 and p.G262_A275del) were also comparable to w/t
AIPL1 in their expression (Fig. 2D) and subcellular localization
(Fig. 2E). However, the nonsense premature translation termina-
tion variants p.W72*, p.W88* and p.W278* (Fig. 2C), and the
frameshift premature translation termination products
p.H93Afs*66 and p.E215Afs*3 (Fig. 2E) formed intracellular inclu-
sions that were visible by immunofluorescent confocal micros-
copy. Although p.W72* and p.W88* were detected by western
blotting (Fig. 2B), p.W278* forms detergent insoluble intracellu-
lar aggregates that can be trapped on a filter (38) and thus did
not resolve efficiently by denaturing SDS-PAGE (Fig. 2A).
Figure 1. AIPL1 variations investigated associated with LCA. (A) Non-synonymous missense and nonsense variations, small insertions and duplications in the coding
sequence of AIPL1 and their predicted changes in the AIPL1 amino acid sequence. (B) Schematic representation of the domain structure of AIPL1. The protein consists
of an amino-terminal FKBP-like domain, a TPR domain that encompasses three consecutive TPR motifs and the primate-specific polyPRD. The diagram indicates which
AIPL1 variants were analysed in this study. (C) Genetic variations in AIPL1 coding and non-coding sequences that induce aberrant pre-mRNA splicing resulting in the
indicated protein isoforms. (D) Schematic representation of AIPL1 protein isoforms encoded by alternative AIPL1 transcripts including in-frame domain deletions as a
result of in-phase exon skipping, frame-shift stop mutations and small insertions and deletions. Inclusion of non-native AIPL1 amino acid sequence induced by a
frame-shift is shown as light grey crossed out boxes.
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Similarly, p.H93Afs*66 and p.E215Afs*3 formed intracellular ag-
gregates of misfolded proteins (Fig. 2E) that were not resolved
efficiently by denaturing SDS-PAGE (Fig. 2D). Interestingly, the
nonsense premature translation termination variant p.Q163*
(Fig. 2A, B and C) and the frameshift premature translation ter-
mination variant p.V249Afs*3 produced as a result of alternative
splicing (Fig. 2D and E) were detected by western blotting but
did not form intracellular aggregates in cells and were similar to
w/t AIPL1 in their subcellular distribution. Finally, nonsense
and frameshift stop mutations resulting in the large C-terminal
truncation of AIPL1 (p.R32*, p.I34Dfs*10, p.F35Lfs*2 and
p.R38Lfs*6) were not detected by western blotting or immuno-
fluorescent confocal microscopy with an antibody directed
against either the C-terminal AIPL1-specific epitope or the N-
terminal myc tag due to their very small size (3 kDa) (Fig. 2A
and B) and were thus not investigated further. In summary, all
the premature translation termination products detected in our
assay, except p.Q163* and p.V249Afs*, formed intracellular pro-
tein inclusions. All the remaining AIPL1 variants were similar to
w/t AIPL1.
Notably, the expression of all the AIPL1 variants investigated
was driven from the same promoter under the same experi-
mental conditions in cells leading to similar or elevated levels
detected by western blotting compared with w/t AIPL1, with the
exception of p.H93Afs*66, p.V249Afs*3 and p.W278* which were
not resolved efficiently by SDS-PAGE. Yet, the formation of in-
tracellular aggregates was evident only for p.W72*, p.W88*,
p.H93Afs*66, p.E215Afs*3 and p.W278* but not p.Q163* and
p.V249Afs*3 or any of the other variants investigated, suggesting
that the formation of these aggregates occurs as a result of mis-
folding rather than due to protein overexpression. Interestingly,
the c.834G>A substitution coding for p.W278* is located in the
final exon of AIPL1 and the resultant transcript may therefore
escape nonsense-mediated mRNA decay (NMD) in vivo in photo-
receptors, whilst the transcripts coding for all the other prema-
ture translation termination products are predicted to be
subject to NMD due to the presence of premature termination
codons. However, if these transcripts were to escape NMD
in vivo, the resultant premature translation termination prod-
ucts would likely misfold leading to loss of function, except in
the case of p.Q163* and p.V249Afs*3 which did not misfold in
cells. Thus, p.Q163* and p.V249Afs*3 as well as all the AIPL1 vari-
ants that that did not misfold in intracellular inclusions were
investigated further to determine their impact on AIPL1
function.
Nucleotide binding facilitates the interaction of AIPL1
with HSP90
AIPL1 can interact with the molecular chaperone HSP90, the
conformational chaperone cycle of which is regulated by ATP
binding and hydrolysis (14). The interaction of AIPL1 with HSP90
as a co-chaperone is poorly understood. We therefore investi-
gated the nucleotide dependence of the interaction of AIPL1
with HSP90 using co-immunoprecipitation and quantitative
ELISA (Fig. 3). Myc-AIPL1 and HA-HSP90 were reciprocally co-
immunoprecipitated (Fig. 3A). Although HA-HSP90 was specifi-
cally co-immunoprecipitated by myc-AIPL1, a small amount of
myc-AIPL1 was non-specifically detected in the absence of HA-
HSP90. The co-immunoprecipitation of HA-HSP90 with myc-
AIPL1 was enhanced by the addition of either ATP (5 mM) or
adenosine diphosphate (ADP) (5 mM), with the addition of ATP
having a greater effect than ADP (Fig. 3B). Conversely, the inter-
action was reduced by the addition of apyrase (Fig. 3C). These
data suggest that AIPL1 preferentially associates with
nucleotide-bound HSP90. Quantitative ELISA corroborated these
findings. The interaction of myc-AIPL1 with untagged purified
HSP90a was significantly enhanced by the addition of 5 mM ATP
or ADP, with steady-state levels attained more rapidly in the
presence of ATP than ADP (Fig. 3D), and the addition of apyrase
significantly reducing the interaction (Fig. 3E). HSP990, a specific
HSP90 inhibitor, also reduced the interaction of myc-AIPL1 with
HSP90a particularly in the absence of added nucleotide (Fig. 3F).
Similar results were obtained with AIPL1 and HSP90b (data not
shown). Altogether, the results confirm that AIPL1 interacts
preferentially with nucleotide-bound HSP90, particularly ATP-
bound HSP90.
The interaction of AIPL1 with HSP90 is reduced by
mutations in the TPR and FKBP-like domains
The interaction of HSP90 with the AIPL1 variants was investi-
gated by directed yeast two-hybrid (Y2H) analysis and by quan-
titative ELISA, and compared with that of w/t AIPL1 to assess
any deficits in HSP90 interaction (Figs 4 and 5). The interaction
with HSP90 lacking the C-terminal MEEVD motif was also inves-
tigated, as this motif is important in mediating the interaction
of the TPR domain with HSP90 (10). In the Y2H assays, yeast co-
transformed with the positive control plasmids, pSos-MAFB and
pMyr-MAFB, grew on selective media at both the permissive
(24C) and restrictive (37C) temperatures (Fig. 4A). The interac-
tion of the Sos-MAFB and Myr-MAFB proteins localized hSos to
the cell membrane via the myristoylation signal, thereby acti-
vating the Ras pathway and rescuing the temperature-sensitive
phenotype of the cdc25H strain on selective media. Yeast co-
transformed with empty pSos and empty pMyr, with empty
pSos and pMyr-HSP90, or with empty pSos and pMyr-
HSP90DMEEVD grew on selective media at the permissive tem-
perature but did not rescue growth at 37C and were therefore
used as internal negative controls in the assay. In the directed
Y2H assays of the AIPL1 variants from coding variations (Fig.
4A), w/t AIPL1 interacted with HSP90 and this interaction was
reduced by deletion of the HSP90 C-terminal MEEVD, confirming
that the MEEVD motif contributes to the binding of AIPL1 to
HSP90. The premature stop mutant p.W278* did not induce
growth at the restrictive temperature, as previously reported
(10). No growth at the restrictive temperature was seen in yeast
cells transformed with HSP90 and the AIPL1 variants p.L17P,
p.C89R and p.E282_A283dup revealing a deficit in their ability to
interact with HSP90. The AIPL1 variants p.G64R, p.V71F,
p.K214N and p.G262S were able to interact with HSP90 in a TPR-
dependent manner similar to w/t AIPL1 in the Y2H assay. It has
previously been reported that p.G262S does not impact AIPL1
function (10,30,37,38). Similarly, p.K214N did not affect AIPL1 in-
teraction with HSP90. However, both c.642G>C (p.K214N) and
c.784G>A (p.G262S) abolish native AIPL1 splicing leading to
the production of alternative isoforms (35). Interestingly, the
p.Q163* variant, which lacks the entire AIPL1 TPR domain, was
able to rescue growth with both HSP90 and HSP90DMEEVD, sug-
gesting non-specific transactivation by p.Q163* in the Y2H as-
say. Western blotting confirmed the expression of the AIPL1
variants in yeast cell lysates (Fig. 4B), with the exception of
p.W278* which is trapped in detergent-insoluble inclusions in
cells (Fig. 2D).
We performed a quantitative ELISA to quantify the interac-
tion of the AIPL1 variants with full-length human HSP90a and
HSP90b (Fig. 4C). The absorbance of each AIPL1 variant was
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normalized to the expression of the variant in the cell lysate
and calculated relative to w/t AIPL1. The ELISA assay corrobo-
rated the findings of the Y2H assay, confirming that p.L17P,
p.C89R and p.E282_A283dup are significantly impaired in their
ability to interact with HSP90a/b compared with w/t AIPL1,
while p.V71F, p.K214N and p.G262S are less severely compro-
mised in their ability to bind HSP90a/b. Interestingly, while
p.G64R was able to interact with HSP90 in the Y2H assay to in-
duce growth, it is clear from the quantitative ELISA assay that
the affinity of binding was reduced compared with w/t AIPL1.
Hence, there is a threshold for AIPL1 HSP90 interaction below
which growth is not induced in the Y2H assay, with the quanti-
tative ELISA able to discriminate deficiencies in interaction.
Interestingly, whilst p.Q163* was able to interact with HSP90 in
a TPR-independent manner in the Y2H assay, the interaction of
p.Q163* and HSP90a/b was completely abolished in the ELISA as-
say. Finally, addition of the MEEVD peptide reduced, but did not
abolish, the interaction of all the HSP90a/b interacting AIPL1
variants, except for p.C89R where peptide competition was less
efficient.
Figure 2. Expression and subcellular localization of AIPL1 variants. (A), (B) and (D) Western blotting analysis of wild-type (w/t) AIPL1 and the indicated AIPL1 variants
(A, B) or AIPL1 protein isoforms (D). The proteins were resolved by SDS-PAGE on a 12% (A, D) or 20% (B) gel. The anti-AIPL1 antibody is directed against a C-terminal
AIPL1 epitope (7) and the anti-myc antibody recognizes the myc tag fused to the N-terminus of AIPL1. GAPDH was detected as a loading control. (C) and (E) Indirect im-
munofluorescent confocal microscopy using anti-myc antibody. The misfolding and aggregation of p.W72*, p.W88*, p.W278*, p.H93Afs*66 and p.E215Afs*3 in visible in-
tracellular inclusions is shown at higher magnification as inserts. Scale bar: 10lm.
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Next, we investigated the interaction of the AIPL1 in-frame do-
main deletions and frameshift stop mutations expressed from the
AIPL1 splice variations (Fig. 5). None of the AIPL1 variants were able
to interact with HSP90 in directed Y2H assays with the exception
of p.V33_Q155del (in-frame deletion of exons 2 and 3) and
p.K214N_E215insVRGRWPG (Fig. 5A). p.K214N_E215insVRGRWPG
mediated a TPR-dependent interaction with HSP90 similar to w/t
AIPL1 despite the insertion of seven residues in the loop connecting
consecutive TPR motifs in the TPR domain. On the other hand, the
recognition of p.V33_Q155del by HSP90 in this assay did not require
the MEEVD motif, deletion of which did not compromise the interac-
tion of p.V33_Q155del with HSP90. All the AIPL1 products were ex-
pressed in yeast (Fig. 5B), except for p.H93Afs*66. Moreover, both
p.H93Afs*66 and p.E215Afs*3 formed intracellular aggregates of mis-
folded proteins in cells (Fig. 2E) and, accordingly, were unable to res-
cue growth at the restrictive temperature in directed Y2H assays
with HSP90 and HSP90DMEEVD (Fig. 5A). The quantitative ELISA (Fig.
5C) confirmed that all of the AIPL1 variants were unable to interact
efficiently with HSP90a/b with the exception of p.V33_Q155del
which was comparable to w/t AIPL1. The interaction of
p.V148_Q155del, p.V156_K214del, p.V249Afs*3 and p.G262_A275del
was effectively abolished, while that of p.V33_I92del, p.H93_Q155del
and p.K214N_E215insVRGRWPG was significantly reduced com-
pared with w/t AIPL1. However, the efficiency of p.K214N_E215in
sVRGRWPG interaction was significantly better than p.V33_I92del
and p.H93_Q155del, and p.K214N_E215insVRGRWPG surpassed the
threshold for growth in the Y2H assay. MEEVD peptide competition
was evident only in the case of w/t AIPL1 and the HSP90a/b interact-
ing products p.V33_Q155del and p.K214N_E215insVRGRWPG, sug-
gesting that features directing the prototypical TPR co-chaperone
chaperone interaction are preserved in these variants.
Mutations in the FKBP-like and TPR domain compromise
the ability of AIPL1 to stabilize PDE6a in the cytosol
We investigated the impact of the AIPL1 variants on the stabili-
zation of PDE6a in the cytosol and on the activity of the PDE6
holoenzyme to gain further insight into how the independently
folded FKBP-like and TPR domains of AIPL1 contribute to rod
cGMP PDE6 processing and activity. We first examined the local-
ization of the rod cGMP PDE6 subunits expressed alone and in
combination, both in the absence and presence of AIPL1. When
expressed alone, PDE6a and PDE6b (Fig. 6A) localized to intracel-
lular membranes, whilst PDE6c (Fig. 6A) and AIPL1 (Fig. 2) were
ubiquitously distributed throughout the cytosol. PDE6a and
PDE6b are targeted to and dock at the cytosolic face of the endo-
plasmic reticulum (ER) following their isoprenylation in the cy-
tosol (40), and their subcellular localization thus overlapped
with that of the ER-resident chaperones binding immunoglobu-
lin protein (BiP) and calnexin or the ER retention signal
Figure 3. Nucleotide-dependent interaction of AIPL1 with HSP90. (A), (B) and (C) Western blotting analysis of the co-immunoprecipitation of HA-HSP90 with myc-
AIPL1. Protein lysates from co-transfected cells were incubated in the absence of nucleotide (A), in the presence of ATP (5 mM) (B), ADP (5 mM) (B) or apyrase (10 units/
ml) (C). Myc-AIPL1 and HA-HSP90 were immunoprecipitated using anti-myc and anti-HA, respectively. Immunodetection was performed with anti-AIPL1 or anti-HA
antibodies. (D), (E) and (F) Quantitative ELISA binding assay of the interaction of myc-AIPL1 with purified human recombinant HSP90a. Increasing volumes of myc-
AIPL1 expressing cell lysates were added to a constant concentration of HSP90a (80 nM). When indicated, incubation was done in the presence of ATP (5 mM) (D, F), ADP
(5 mM) (D), apyrase (10 units/ml) (E) or HSP990 (5 mM) (F). Statistically significant differences are indicated by 2 (p0.01) or 3 (p0.001) asterisks.
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sequence KDEL (Fig. 6B). When co-expressed, PDE6a and PDE6b
co-localized at the ER, and PDE6c was recruited to the ER when
co-expressed with either PDE6a or PDE6b (Fig. 6C). When co-
expressed, there was no change in the respective subcellular
localizations of AIPL1 and PDE6c in the cytosol (not shown).
However, while AIPL1 was recruited to the intracellular ER
membranes by PDE6b, AIPL1 induced the redistribution of
PDE6a from the ER resulting in the co-localization of AIPL1 and
PDE6a in the cytosol (Fig. 6C). When PDE6a, b and c were co-
expressed, all three subunits were targeted to the ER irrespec-
tive of the presence of AIPL1 (Fig. 6D).
To characterize the redistribution of PDE6a to the cytosol by
AIPL1, we assessed the relocalization of PDE6a in relation to the
ER marker BiP as we were unable to triple label cells for PDE6a,
AIPL1 and an ER marker due to the lack of suitable antibodies
(Fig. 7A). The just another co-localization plugin (JACoP) for
ImageJ (41) was used to assess the Pearson’s intensity correla-
tion and Manders’ overlap coefficient for the co-localization of
PDE6a and BiP in the cytoplasm of cells in the absence and
presence of AIPL1. In the absence of AIPL1, PDE6a co-localized
with BiP (Fig. 7A) (r¼ 0.876 0.01, M1¼ 0.866 0.06 where
M1¼ fraction PDE6a overlapping BiP). In the presence of
AIPL1, there was a significant decrease in the intensity correla-
tion (r¼ 0.6660.03, p< 0.001) and Manders’ overlap coefficient
(M1¼ 0.2460.03, p< 0.001) of PDE6a and BiP as a result of the re-
distribution of PDE6a to a homogenous localization throughout
the cytosol (Fig. 7A). In agreement with these findings, fraction-
ation of cell lysates co-expressing AIPL1 and PDE6a confirmed
that AIPL1 increased the levels of PDE6a in the cytosol, and that
this occurred in a proteasome-dependent manner (Fig. 7B).
Hence, AIPL1 recruits PDE6a to the cytosol, where AIPL1 stabil-
izes PDE6a against proteasomal degradation.
We next investigated whether the AIPL1 variants could effi-
ciently mediate the redistribution of PDE6a from the intracellu-
lar cell membranes to the cytosol compared with w/t AIPL1 (Fig.
7C). The localization of PDE6a was scored based on the morpho-
logical distribution in cells. A perinuclear distribution that was
particulate in appearance was scored as ER (Fig. 7A, top),
Figure 4. Interaction of LCA-linked AIPL1 variants with HSP90. (A) Qualitative analysis of the interaction between AIPL1 and HSP90 through directed Y2H assays. Yeast
cdc25H strain was co-transformed with pMyr bearing bovine HSP90a(204–733) or HSP90a(204–733DMEEVD) and pSos bearing wild-type (w/t) AIPL1 or the AIPL1 variants
indicated. Serial dilutions were tested for their ability to grow on selective media under permissive (24 C) or restrictive (37 C) conditions, respectively. (B) Western blot-
ting analysis of protein expression in yeast cell extracts of AIPL1 variants using anti-Sos antibody. (C) Quantitative ELISA analysis of the interaction between w/t AIPL1
or the AIPL1 variants indicated with purified human recombinant HSP90a and b. The absorbance of each interaction was normalized to the expression level detected
by western-blotting and plotted relative to w/t AIPL1¼1.0. White bars indicate addition of purified MEEVD peptide for competitive binding to AIPL1. Assays were per-
formed in triplicates. All AIPL1 variants showed statistically significant differences (p0.01) with respect to w/t AIPL1 with the exception of the variants demarcated by
NS (p>0.01).
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whereas a smooth homogeneous distribution throughout the
cytoplasm was not counted as ER (Fig. 7A, bottom). The percent-
age of PDE6a expressing cells in which PDE6a localization was
scored as ER was quantified and the reciprocal values normal-
ized to w/t AIPL1 to show a deficit in this function (Fig. 7C). Only
AIPL1 p.K214N and p.G262S were comparable to w/t AIPL1 in
mediating the redistribution of PDE6a to the cytosol, where co-
localization with p.K214N and p.G262S was evident (Fig. 7C and
D). In contrast, all the remaining AIPL1 variants were unable to
efficiently mediate the relocalization of PDE6a to the cytosol
compared with w/t AIPL1, and PDE6a remained at the intracellu-
lar ER membranes, as exemplified by AIPL1 p.Q163* and
p.V33_Q155del (Fig. 7C and D). Importantly, we found that the
ability of AIPL1 to redistribute PDE6a to the cytosol and protect
PDE6a from proteasomal degradation was dependent on HSP90
as these AIPL1-mediated functions were completely abolished
following the inhibition of HSP90 activity with geldanamycin,
17-N-allylamino-17-demethoxygeldanamycin (17-AAG) or
HSP990 (Fig. 7E and F).
The regulation of rod cGMP PDE6 activity is
compromised by mutations in the AIPL1 FKBP-like and
TPR domains
Finally, we investigated the impact of the AIPL1 variants on
PDE6 activity (Fig. 8). We conducted our assays in the presence
of the holoenzyme as the PDE6c subunit is critical for the proper
Figure 5. Interaction of LCA-linked AIPL1 protein isoforms with HSP90. (A) Qualitative analysis by directed Y2H assays. Yeast cdc25H strain was co-transformed with
pMyr-HSP90a(204–733) or pMyr-HSP90a(204–733DMEEVD) and pSos bearing wild-type (w/t) AIPL1 or the AIPL1 protein isoforms indicated. Serial dilutions were tested
for their ability to grow on selective media at the permissive (24 C) or restrictive (37 C) temperature. (B) Western blotting analysis of the expression of the AIPL1 pro-
tein isoforms in yeast cell extracts using the anti-Sos antibody. (C) Quantitative ELISA analysis of the interaction between w/t AIPL1 or the AIPL1 protein isoforms indi-
cated with purified human recombinant HSP90a and b. The absorbance of each interaction was normalized to the expression level detected by western-blotting and
plotted relative to w/t AIPL1¼ 1.0. White bars indicate addition of purified MEEVD peptide for competitive binding to AIPL1. Assays were performed in triplicates. The
differences in binding to HSP90 with respect to w/t AIPL1 were statistically significant (p0.01) for most of the AIPL1 proteins isoforms analysed with the exception of
that demarcated by NS (p> 0.01).
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folding, processing and activity of holoPDE6 in vivo (42). In the
absence of PDE6, AIPL1 had no effect on the intracellular levels
of cGMP in transfected cells, which remained at background
level. The PDE6 holoenzyme alone increased cGMP levels above
background to a small extent. However, AIPL1 significantly in-
creased the cGMP levels above basal levels. Analysis of the
AIPL1 variants from the coding variations (Fig. 8A) revealed that
p.L17P and p.G64R were completely unable to modulate PDE6
activity above basal levels, whilst p.V71F, p.C89R and Q163*
were severely compromised. In contrast, p.K214N, p.G262S and
p.E282_283dup significantly increased PDE6 activity above basal
levels, however, p.E282_283dup was not as efficient as w/t
AIPL1. Analysis of the AIPL1 variants from the splicing varia-
tions (Fig. 8B) revealed that all the variants were significantly
and severely impaired in their ability to modulate PDE6 activity
compared with w/t AIPL1. Only p.V33_Q155del, p.V156_K214del,
p.K214N_E215ins and p.G262_A275del induced a slight increase
in cGMP above basal levels. In summary, p.K214N and p.G262S
were the most efficient compared with w/t AIPL1 in modulating
the basal activity of the PDE6 holoenzyme, whilst the function
of all the other AIPL1 variants was compromised to various
degrees.
Discussion
AIPL1, a retina-specific HSP90 co-chaperone, facilitates the
proper folding and assembly of the visual effector enzyme
PDE6. Here, we provide unequivocal experimental evidence that
the AIPL1 variations investigated in this study lead to significant
and severe functional deficits in the resultant AIPL1 protein
confirming their disease-causing status. In addition, our find-
ings expand the understanding of the role of AIPL1 as a retina-
specific chaperone for PDE6 and deliver insights into the molec-
ular mechanisms of pathogenesis associated with these AIPL1
variations. Such detailed functional studies are lacking in the vi-
sual sciences literature and thereby severely limit our under-
standing of inherited retinal disease, which now presents the
commonest cause of blindness in working age adults in UK and
the second commonest in childhood.
Our findings are summarized in Figure 9. We first investi-
gated the impact of domain-specific changes in AIPL1 on the in-
teraction with the molecular chaperone HSP90. Structural
models of AIPL1 (24,32) confirm that each of the three TPR mo-
tifs consists of a pair of anti-parallel a-helices (helix A and B),
with sequentially arranged consecutive TPR motifs forming an
amphipathic groove proposed to accommodate the terminal
EEVD residues of molecular chaperones (Fig. 9). Our data show
that disruption of the AIPL1 TPR domain as a result of deletions
(p.V156_K214del, p.G262_A275del), insertions (p.K214N_E215
insVRGRWPG), duplications (p.E282_A283dup) or C-terminal
truncation (p.V249Afs*3, p.Q163*) compromised the interaction
with HSP90 as expected. AIPL1 p.K214N_E215insVRGRWPG was
the least compromised of all the AIPL1 TPR domain variants,
likely due to the fact that the insertion of seven amino acid
Figure 6. Subcellular localization of rod PDE6 subunits and AIPL1-mediated redistribution of PDE6a. Indirect immunofluorescent confocal microscopy of single (A and
B), double (C) or quadruple transfected cells (D) with AIPL1, PDE6a, PDE6b and/or PDE6c subunits as indicated. (A) Localization of PDE6a, PDE6b and PDE6c in single
transfected cells as indicated. (B) Co-localization of PDE6a and PDE6b with the endogenous ER markers BiP and KDEL is shown by immunofluorescence (at higher mag-
nification as inserts), and western blotting shows fractionation with calnexin. (C) Co-localization of AIPL1, PDE6a, PDE6b and PDE6c as indicated in double transfected
cells. PDE6a is targeted to the ER (A and B) but is redistributed to the cytosol in the presence of AIPL1 (C). (D) Co-localization of AIPL1 and PDE6a in quadruple transfected
cells. Scale bar: 10lm.
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Figure 7. AIPL1-mediated rod PDE6a redistribution from the ER to the cytosol is proteasome dependent and requires HSP90 activity. (A) Immunofluorescent confocal
microscopy of PDE6a and endogenous BiP in the absence and presence of AIPL1. The co-localization of PDE6a with BiP was determined using the ImageJ JACoP (41). The
cell outlines are demarcated by a white dashed line. (B) Western blotting analysis of PDE6a alone or in the presence of AIPL1 in the membrane and cytosolic fractions,
in the absence and presence of proteasome inhibitor (50lM MG132, 4 h). The anti-Xpress (PDE6a), anti-myc (AIPL1) and anti-GAPDH (loading control) antibodies were
used. AIPL1 induces the subcellular relocalization of PDE6a from the ER to the cytosol where it stabilizes PDE6a to proteasomal degradation. (C) Quantitative analysis of
the ability of the AIPL1 variants and protein isoforms to redistribute PDE6a to the cytosol compared with w/t AIPL1¼1. (D) Indirect immunofluorescent confocal mi-
croscopy of PDE6a relocalization to the cytosol in the presence of the AIPL1 variants p.K214N, p.G262S, p.Q163* or p.V33_Q155del. (E) Western blotting analysis of PDE6a
alone or in the presence of AIPL1 in the membrane and cytosolic fractions, in the absence and presence of the inhibitor HSP990 (1lM). (F) Quantitative analysis of the
ability of AIPL1 to redistribute PDE6a to the cytosol in the absence or presence of the inhibitors HSP990, geldanamycin and 17-AAG (1lM).
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resides in the loop connecting the first and second TPR motifs
may have less of an impact on the topological arrangement of
these motifs (Fig. 9). On the other hand, the small deletion
p.G262_A275del and duplication p.E282_A283dup both com-
pletely abolished HSP90 interaction, likely due to their signifi-
cant impact on the topological packing of the TPR domain.
AIPL1 p.G262_A275del leads to the loss of the last two residues
of the second TPR motif and almost the entire helix A of the
third TPR motif (Fig. 9). Helix A of this TPR motif includes TPR
consensus residues required for the antiparallel packing of the
helix A and B a-helices, as well as residues predicted to mediate
tight electrostatic interactions with the EEVD motif of molecular
chaperones through the formation of a peptide-binding pocket
(10). Similarly, the duplication of two residues at the beginning
of helix B of the third TPR motif in p.E283_A283dup is expected
to disrupt the packing of adjacent anti-parallel a-helices of this
motif and consequently impair HSP90 interaction. In-frame de-
letion of the interdomain connecting loop between the FKBP-
like and TPR domain and the first TPR motif in p.V156_K214del
similarly completely compromised the interaction of AIPL1 with
HSP90, as did C-terminal truncation of AIPL1 (p.V249Afs*3 and
p.Q163*) (Fig. 9). AIPL1 p.V249Afs*3 is characterized by the loss
of the PRD and half of the TPR domain, whilst AIPL1 p.Q163*
leads to the loss of the entire TPR domain and PRD (Fig. 9). The
rescue of growth by p.Q163* in the Y2H assay irrespective of the
deletion of the HSP90 MEEVD motif suggests transactivation by
this variant in the Y2H assay. Importantly, our data show that
p.V156_K214del and p.K214N_E215insVRGRWPG, the AIPL1 pro-
tein isoforms translated as a result of alternative transcription
of c.642G>C(p.K214N), have a reduced affinity of binding with
HSP90 while the missense variant p.K214N had a minimal effect
on the interaction with HSP90 in comparison to wild-type
AIPL1. Similarly, p.V249Afs*3, which is produced as a result of
alternative transcription from c.784G>A(p.G262S), is also un-
able to bind HSP90, whereas p.G262S was comparable to wild-
type AIPL1 in binding HSP90. This confirms alternative splicing
and resultant AIPL1 loss of function as the underlying cause
of pathogenesis for AIPL1 p.K214N and p.G262S, and stresses
the importance of defective splicing as a disease-causing
mechanism.
Our data show that with the exception of p.K214N and
p.G262S, all of the AIPL1 TPR domain variants also affect the rod
cGMP PDE6 activity (Fig. 9). Similarly, it has been reported that
the p.C239R missense variant in the AIPL1 TPR domain leads to
the loss of cone PDE6 activity (30). Interestingly, loss of the en-
tire TPR domain in p.Q163* severely compromised the ability of
AIPL1 to modulate PDE6a redistribution and the activity of the
PDE6 holoenzyme. NMR data reveal that the FKBP-like domain
of human AIPL1 can attain the native fold in the absence of the
TPR domain and successfully bind a farnesyl moiety (33). In an-
other study, the AIPL1 FKBP-like domain bound a farnesyl probe
comparably to full-length AIPL1 in the absence of the TPR do-
main, which itself was unable to bind the farnesyl probe and
did not alter the affinity of the FKBP-like domain for the probe
(32). Not only does this suggest that each domain of AIPL1 plays
a unique role in chaperoning PDE6 but together with our data
also suggest that binding of the farnesyl moiety to the FKBP-like
domain alone is not sufficient for AIPL1 to fulfil its role in modu-
lating PDE6 stability and activity, which also requires a func-
tional interaction with HSP90. This is supported by the finding
that reciprocal chimeras of the FKBP-like and TPR domains
from AIPL1 and AIP, which is unable to bind a farnesyl moiety,
both completely failed to modulate the activity of the cone PDE6
holoenzyme (30). It is also interesting that while the small TPR
insertion p.K214N_E215insVRGRWPG had a relatively less se-
vere impact on HSP90 interaction, the impact on PDE6 was sig-
nificant (Fig. 9). Hence, the integrity of this domain and its
ability to mediate an interaction with HSP90 is critically impor-
tant for AIPL1 to fulfil its role in PDE6 stability and activity. In
addition to the integrity of each domain, we propose that their
relative orientation and organization is also important for the
overall function of AIPL1. Structural models of mouse and hu-
man AIPL1 revealed that the FKBP-like domain and TPR domain
of AIPL1 fold independently with no obvious interdomain con-
tacts and can adopt a range of relative orientations, some of
which may be constrained by the length of the flexible interdo-
main loop connecting the FKBP-like and TPR domain (24,32).
The proposed importance of the integrity and orientation of
both domains is supported by our findings that missense
changes and in-frame deletions in the AIPL1 FKBP-like domain
Figure 8. Heterologous rod PDE6 activity in the presence of the AIPL1 variants
and protein isoforms. (A) and (B) Quantitative analysis of the cGMP concentra-
tion from cells expressing the PDE6 holoenzyme (a, b and c) alone, and in
the presence of wild-type (w/t) AIPL1, the AIPL1 variants (A) or AIPL1 isoforms
(B) as indicated. Assays were performed at least three times and in triplicate.
All AIPL1 variants or AIPL1 protein isoforms showed statistically significant
differences (p0.01) compared with w/t AIPL1 except p.K214N and p.G262S that
did not have a significant effect on PDE6 activity (NS) (p> 0.05).
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conversely compromise the ability of AIPL1 to interact with
HSP90 (Fig. 9).
Structural data reveal that the typical FKBP fold is conserved
in human AIPL1 and is composed of an a-helix surrounded by a
five-stranded b-sheet to create a hydrophobic cavity analogous to
the FKBP ligand-binding site (24,33) (Fig. 9). The FKBP-like domain
of AIP and AIPL1 uniquely contain an intervening loop between
the fourth and fifth strands of the b-sheet thought to occlude the
hydrophobic cavity of the FKBP-like domain and influence the rel-
ative domain orientation by engaging in steric clashes with the
TPR domain (24,33,44). The FKBP-like domain missense variants
p.L17P, p.G64R and p.C89R were unable to efficiently modulate
PDE6 activity and were also inefficient at binding HSP90 (Fig. 9).
The missense variant p.V71F was also unable to modulate PDE6
activity but was the least compromised in binding HSP90 com-
pared with the other missense variants. AIPL1 p.V71F has been
reported to bind a farnesyl moiety comparably to wild-type AIPL1
and circular dichroism (CD) spectra revealed that there are no
global conformational changes in the mutant protein (32). Yet,
p.V71F was deficient in driving cGMP hydrolysis by cone PDE6
(30), suggesting that farnesyl binding alone is not sufficient for
the overall function of AIPL1. Like p.V71F, CD analysis of p.C89R
ruled out global conformational changes of the mutant protein
(32), however, both these residues are embedded in the core FKBP
domain and may alter or destabilize the FKBP fold (Fig. 9). AIPL1
p.C89R has been reported to drastically reduce the interaction of
AIPL1 with a farnesyl motif and consequently severely impair the
activity of cone PDE6 (30,32). Similarly, we found that p.C89R was
severely impaired in the ability not only to modulate rod PDE6 ac-
tivity but also to bind HSP90. The residues C89 and L147 are in close
proximity in a hydrophobic pocket in the structural model of AIPL1
and flank the beginning and end, respectively, of the unique insert
region of the FKBP-like domain (32,33). It was proposed that C89
and L147 are essential for the conformation of the insert region
that may play a direct and critical role in farnesyl binding.
Interestingly, a direct but weak and transient interaction was re-
ported to be mediated by residues in the analogous unique insert
region of AIP and HSP90, thereby rendering the FKBP-like ligand
binding domain accessible (44). Hence, missense mutations in the
AIPL1 FKBP-like domain may compromise the integrity of the FKBP
fold and the interaction with the isoprenyl motif, alter the requisite
domain orientations and reduce the efficiency of HSP90 interac-
tion. Similarly, p.L17P and p.G64R are highly conserved residues
that are likely to be of structural or functional importance (Fig. 9).
Notably, in-frame deletions in the AIPL1 FKBP-like domain
similarly significantly impaired the interaction with HSP90. The
in-frame deletions p.V33_I92del (in-frame deletion of exon 2)
and p.H93_Q155del (in-frame deletion of exon 3) result in the
loss, respectively, of the first and second halves of the unique in-
sert region and are therefore likely to have a significant impact on
the integrity of the FKBP fold, farnesyl binding or the relative ori-
entation of the FKBP-like domain (Fig. 9). Deletion of only eight
residues (p.V148_Q155del) near the interdomain connecting linker
between the FKBP-like and TPR domain severely compromised
AIPL1 activity in relation to both PDE6 and HSP90, suggesting this
may have a very significant and severe effect on the relative ori-
entations of the two domains. AIPL1 p.H93_Q155del and
p.V148_Q155del are the resultant protein isoforms from alterna-
tive transcription of c.465G>T(p.Q155H), confirming aberrant
transcription with a consequent impact on protein function as
the underlying cause of pathogenesis for this AIPL1 variation.
Finally, a large 122-residue in-frame deletion of the entire FKBP-
like domain in p.V33_Q155del (in-frame deletion of exons 2 and 3)
was completely deficient in modulating PDE6 activity but retained
Figure 9. Summary of the functional impacts of the AIPL1 variants. (A) Summary
of the effect of the AIPL1 variants on HSP90 interaction, PDE6a redistribution and
PDE6 activity. (B) Pymol cartoon showing position of AIPL1 mutations: AIPL1
(green) with the position of missense (p.L17P, p.G64R, p.V71F, p.C89R, p.K214N,
p.G262S, cyan sticks), nonsense (p.R32*, p.W72*, p.W88*, p.Q163*, p.W278*, yellow
sticks) and frameshift premature translation mutations (p.F35Lfs*2, p.I34Dfs*10
and p.R38Lfs*6, orange sticks) is shown. Magenta sticks show the position of the
duplication (p.E282_A283dup). (C) AIPL1 (grey) with regions of structure coloured to
indicate deletions, insertions and frameshift premature translation mutations re-
sulting from aberrant AIPL1 splicing. p.V33_I92del (in-frame deletion of exon 2),
red; p.H93_Q155del (in-frame deletion of exon 3), blueþgreen; p.V33_Q155 (in-
frame deletion of exons 2 and 3), redþblueþ green; p.V148_Q155, green;
p.V156_K214del, yellow; p.K214N_E215insVRGRWPG, orange; p.G262_A275del, ma-
genta. H93Afs*66, E215Afs*3 and V249Afs*3 represent points of frameshift leading
to the inclusion of non-AIPL1 sequences and early termination, cyan sticks. The
model of AIPL1 (B and C) was built using Phyre2 (48).
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the ability to interact with HSP90 (Fig. 9). This suggests that the
TPR domain of AIPL1 in isolation can mediate an interaction with
HSP90, as conversely the FKBP-like domain in isolation can medi-
ate an interaction with farnesyl, but efficient binding of both are
required for PDE6 activity.
In agreement with previously published data (24), we de-
tected an increase in cGMP concentrations in the presence of
AIPL1 following heterologous reconstitution of the rod PDE6 ho-
loenzyme. Similarly, it was previously reported that AIPL1 could
interact with the assembled rod PDE6 holoenzyme to inhibit the
basal activity, and that AIPL1 had no effect on the catalytic ac-
tivity following limited proteolysis of the rod PDE6c subunits
(24). In contrast, AIPL1 enhanced the catalytic activity of the
heterologously reconstituted cone PDE6 holoenzyme, and this
occurred more efficiently following trypsin treatment to relieve
the PDE6c inhibition of the catalytic cone PDE6a’ subunits (30).
Although cone PDE6 is found predominantly in soluble retinal
fractions, rod PDE6 is predominantly found at the membrane
mediated primarily by the geranylgeranylated C-terminus of
rod PDE6b (45). Hence, the mechanism of AIPL1 action during
rod and cone PDE6 assembly and activity may differ to accom-
modate these differences between rod and cone PDE6. We con-
firm here that the interaction of AIPL1 and HSP90 is critically
important to facilitate the stable assembly of the rod PDE6 holo-
enzyme. Our data confirm that AIPL1 promotes the stability of
PDE6a in the cytosol in an HSP90-dependent manner and pro-
tects PDE6a from proteasomal degradation, as seen in ex vivo
retinal explants from the Aipl1 knockout mice (27). AIPL1 can
bind to the assembled rod PDE6 holoenzyme (24) and may in-
hibit the catalytic activity until targeted translocation to the
outer segment is achieved via delivery to the connecting cilium.
This mechanism is analogous to that involving the role of
HSP90 and substrate-specific TPR domain co-chaperones in the
functional maturation and targeted translocation of other
HSP90 substrates. However, while AIPL1 and HSP90 play a very
important role in the stable assembly of the PDE6 holoenzyme,
the mode of delivery to the connecting cilium is still unknown.
In summary, we conclude that the integrity of the FKBP-like
domain and the TPR domain of AIPL1, as well as their relative
orientation or organization is critical for AIPL1 to fulfil its func-
tion as a retinal chaperone for PDE6 in conjunction with HSP90.
Moreover, the function of AIPL1 in rod PDE6 assembly and activ-
ity is fundamentally dependent on HSP90. Future cellular and
structural studies will be necessary to fully understand the req-
uisite domain orientations and regulation thereof.
Materials and Methods
AIPL1 nomenclature
The AIPL1 exon numbering is according to the Ensembl
Transcript ENST00000381129 (RefSeq NM_014336, NP_055151).
Nomenclature of AIPL1 sequence variants followed Human
Genome Variation Society guidelines.
Cell culture and transfection
Chinese hampster ovary and human embryonic kidney
(HEK293T) cells were grown in Dulbecco’s modified Eagle’s me-
dium (DMEM)/F12 or DMEM, respectively, (Invitrogen) with 10%
heat inactivated fetal bovine serum, 100 units/ml of penicillin
and 100 mg/ml of streptomycin with an atmosphere of 6% CO2 at
37C. For maintenance, cells were passaged every 3–4 days. Cells
were seeded into eight-well chamber slides (3.5 104 cells per
well) or into six-well plates (5 105 cells per well) for immuno-
fluorescence and western blotting, respectively. Cells were
transfected using TransIT-LT1 transfection reagent according to
the manufacturer’s instructions (Mirus). Where indicated, the
HSP90 inhibitor HSP990 (1lM) (Novartis) or the proteasome in-
hibitor MG132 (50 lM) (Enzo Life Sciences) were added to the cell
cultures.
Microorganisms
For cloning and amplification of plasmid DNA, the Escherichia coli
strain DH5a [fhuA2 D(argF-lacZ)U169 phoA glnV44 U80 D(lacZ)M15
gyrA96 recA1 relA1 endA1 thi-1 hsdR17] from New England Biolabs
(NEB) was used. The Saccharomyces cerevisiae strain cdc25H
(Mata ura3-52 his3-200 ade2-101 lys2-801 trp1-901 leu2-3 112
cdc25-2 Galþ) from CytoTrapXR (Stratagene) was used to perform
Y2H assays.
DNAmanipulation and plasmids
General DNA methods were performed using standard tech-
niques. To express myc-tagged AIPL1 in cells, pCMV-Tag3C-
AIPL1 was used (38). Plasmid pcDNA3-HA-HSP90b was a gift
from William Sessa (Addgene plasmid # 22 487). For the Y2H as-
says the plasmid pSos-AIPL1, pMyr-HSP90a(204–733) and pMyr-
HSP90aDMEEVD(204–728) were used (10). Mutagenesis of specific
residues in AIPL1 were carried out by PCR site-directed muta-
genesis using the Q5 Site-Directed Mutagenesis Kit (NEB). All
plasmids were confirmed by Sanger sequencing (Source
Bioscience).
Cloning of rod PDE6 expression constructs
The cDNAs of rod PDE6a and PDE6c subunits were amplified by
PCR using human retina cDNA (Clontech) as template, PDE6b
cDNA was amplified from WERI-Rb-1 cDNA. Primers used for
PCR were AA-325 (50-CGGGGTACCTGGCGAGGTGACAGCAGAG
GAGG-3‘) and AA-326 (50-CATCCAAGTCCTGCTGCATCCAGTAA
TCTAGACTAG-30) for amplification of PDE6a, AA-331 (50 CGA
ATTCGGTCGACCAGCCTCAGTGAGGAGCAGGCCCGGAGC-30) and
AA-332 (50-GCACCCAAGTCTTCAACCTGCTGTATCCTGTGACTCG
AGCGG-30) for amplification of PDE6b, and AA-329 (50-CCG
GAATTCGGAACCTGGAACCGCCCAAGGCTGAG-30) and AA-330
(50-GCTGGCCCAATATGGCATCATCTAGGGTACCCCG -30) for
amplification of PDE6c. PDE6a was inserted into pcDNA3.1-His/-
A (Invitrogen) using restriction sites KpnI/XbaI, PDE6b was
inserted into pCMV-HA (Clontech) using restriction sites SalI/
XhoI, and PDE6c was inserted into pCMV-myc (Clontech) using
restriction sites EcoRI/KpnI. All constructs were verified by
sequencing (Microsynth AG, Balgach, Switzerland).
Y2H assays
Assays were performed according to the manufacturer’s in-
structions (CytoTrapXR; Stratagene). The vectors pMyr and pSos
or their derivatives were co-transformed using the lithium ace-
tate method (46) into the temperature-sensitive mutant strain
cdc25Ha. Yeast co-transformants were selected on synthetic
dextrose (SD) medium deficient for uracil and leucine (-UL). To
perform qualitative analysis of the two-hybrid interactions, at
least three colonies from every co-transformation were cultured
overnight in selective liquid SD medium (-UL) and growing cul-
tures were adjusted to an optical density at 600 nm (A600) of 0.5.
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Serial 1:10 dilutions of the yeast cultures were prepared and the
cellular suspensions were spotted onto synthetic galactose
plates lacking -UL. Growth was monitored at 24C and at the re-
strictive temperature of 37C. Various pSos and pMyr constructs
provided with the two-hybrid system were used as controls for
positive and negative interactions. Protein expression was veri-
fied according to the manufacturer’s instructions by resolving
yeast cell extracts obtained through the trichloroacetic acid pre-
cipitation method by SDS-PAGE, followed by western blotting
using the anti-Sos antibody (1:250) (Transduction Laboratories).
Immunocytochemistry
Twenty-four hours after transfection, cells were fixed with 4%
paraformaldehyde for 10 min and permeabilized in 0.5% Triton
X-100 for 10 min. Non-specific binding was blocked using 3% bo-
vine serum albumin (BSA), 10% donkey serum in PBS for 1 h at
room temperature. Cells were then incubated for 1 h with either
mouse monoclonal anti-myc (1:500) (clone 9E10, Sigma), mono-
clonal mouse anti-Xpress (1:100) (Invitrogen), rabbit monoclonal
anti-PDE6b (1:500) (ThermoFisher Scientific) or rabbit polyclonal
antisera anti-AIPL1 (1:250) (38), mouse monoclonal anti-KDEL
(1:250) (clone 10C3, Enzo Life Sciences) or rabbit anti-GRP78/BiP
(1:250) (GL-19, Sigma). Primary antibody incubation was fol-
lowed by three washes with PBS and a 1 h incubation with sec-
ondary antibodies, Cy3-conjugated donkey anti-mouse (1:100)
(Jackson ImmnoResearch), donkey anti-mouse Alexa 594 (1:600)
(ThermoFisher Scientific) or donkey anti-rabbit Alexa 488 (1:600)
(ThermoFisher Scientific). Cells were washed three times in
PBS and incubated with 4’,6-diamidino-2-phenylindole (DAPI)
(2 mg/ml) for 5 min, mounted in fluorescent mounting medium
(Dako) and visualized with a Zeiss LSM710 laser scanning confo-
cal microscope. The images were exported from LSM Browser
and prepared using ImageJ and Adobe Photoshop.
Cells extracts and immunoblotting
Transfected cells were washed twice in cold PBS and incubated
for 10 min in radioimmunoprecipitation assay buffer (50 mM
Tris–HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% so-
dium deoxycholate, 0.1% SDS) with 2% protease inhibitor cock-
tail (Sigma) at 4C. Cell lysates were sonicated and centrifuged
at 13 000rpm for 30 min at 4C. The protein concentration in the
soluble fraction was determined using the bicinchoninic acid
assay (ThermoScientific) and then normalized to the same
amount using 2 Laemmli sample buffer. For subcellular frac-
tionation, cell lysis was performed in isotonic buffer (10 mM
Tris–HCl pH 7.4, 2 mM EDTA, 250 mM sucrose) using a syringe
and a 20 gauge needle followed by centrifugation at 90 000g to
obtain a cytosolic and ER-enriched fraction. Protein extracts
were resolved by denaturing SDS-PAGE and transferred onto nitro-
cellulose membranes. Immunodetection of myc-tagged proteins
was carried out using mouse monoclonal anti-myc (1:1000) (clone
9E10, Sigma). Rabbit polyclonal (Y-11) anti-HA antibody (1:1000)
was purchased from Santa Cruz Biotechnology. Rabbit polyclonal
antisera anti-AIPL1 (1:1000) (Ab-hAIPL1) has been described previ-
ously (38). PDE6a and PDE6b were detected with mouse monoclo-
nal anti-Xpress (1:250) and rabbit polyclonal anti-PDE6b (1:1000),
respectively, from Thermo Scientific. The expression of ER
markers was detected using rabbit polyclonal anti-calnexin
(1:1000) from Enzo Life Sciences. Loading controls were detected
using mouse monoclonal anti-glyceraldehyde 3-phosphate
dehydrogenase (1:30 000) from Sigma. Goat anti-mouse (1:30 000)
and anti-rabbit (1:30 000) secondary antibodies conjugated with
horseradish peroxidase were from Pierce Biotechnology. The ECL
plus enhanced (GE Healthcare) or the Luminata Crescendo
(Millipore) chemiluminescent detection reagents were used ac-
cording to the manufacturer’s instructions. Western blot densi-
tometry was performed using ImageJ.
Immunoprecipitation
Twenty-four hours after transfection, cells were lysed in 20 mM
Tris–HCl pH 7.5, 100 mM NaCl, 5 mM MgCl2, 0.5% Triton X-100,
1 mM phenylmethylsulfonyl fluoride, 2% protease inhibitor cock-
tail. Myc-AIPL1 and HA-HSP90 were immunoprecipitated using
mouse monoclonal anti-myc (1:250) (clone 9E10, Sigma) or mouse
monoclonal anti-HA (1:250) (HA-7, Sigma) for 1–2 h at 4C with ro-
tation. The immunoprecipitates were incubated with 30ll of
Dynabeads Protein G (Invitrogen) for 1 h. Beads were washed ex-
tensively with the same buffer, resuspended in 2 Laemmli sam-
ple buffer, and proteins analysed by SDS-PAGE and
immunoblotting as described earlier. Where indicated, 5 mM ATP
(Sigma), 5 mM ADP (Sigma) or Apyrase (10 units/ml) (NEB) were
added to the lysates just before incubating with the antibodies.
HSP90 ELISA
The assays were performed in Immulon 4HBX 96-well plates
(Fisher Scientific). Expression and purification of the His-tagged
human HSP90a and b, was performed as previously described
(47). HSP90a (80 nM) or HSP90b (80 nM) in 100 mM NaHCO3 pH 8.5
was added to the wells (100 ll/well) and incubated at 4C for 1 h.
BSA was added to adjacent wells at a concentration of 0.1% (w/
v) as a control for non-specific binding. Wells were blocked with
1% blocking reagent (Sigma) in 100 mM NaHCO3 pH 8.5 (300ll/
well) for 1 h at 4C and then washed three times with chilled
TBST (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 0.075% Tween-20) to
remove excess of protein. Cell lysates from transfected cells
were added to the wells in lysis buffer (20 mM Tris–HCl pH 7.5,
100 mM NaCl, 5 mM MgCl2, 0.075% Tween-20) containing 2% of
protease inhibitor cocktail. Increasing volumes of myc-AIPL1
expressing cell lysate (from 10 to 100 ll) was added to lysis buf-
fer to a final volume of 100 ll to determine the kinetics of the in-
teraction of myc-AIPL1 with HSP90a/b. For comparison of the
AIPL1 variants to w/t AIPL1, 50 ll cell lysates were added to lysis
buffer to a final volume of 100 ll. After 1 h of incubation at 4C,
the wells were washed five times with chilled lysis buffer
(200ll/well). Mouse anti-myc antibody (clone 9E10, Sigma)
(1:1000) in lysis buffer containing 0.1% blocking reagent was
then added to each well for 1 h (100 ll/well). After five washes,
the anti-mouse HRP conjugated antibody (1:10 000) was added
and incubated for another hour. After five final washes, the sub-
strate 3,30,5,50-tetramethylbenzidine (Sigma) (100 ll/well) was
added for colorimetric detection and the plate incubated at 30C
for 30 min with shaking. The reaction was stopped with an
equal volume of 0.5 M H2SO4 and the absorbance measured at
450 nm. For comparison of the AIPL1 variants to w/t AIPL1, the
absorbance measured at 450 nm was normalized to the expres-
sion level in cell lysates detected by SDS-PAGE and western
blotting. Where indicated, 5 mM ATP (Sigma), 5 mM ADP (Sigma),
Apyrase (10 units/ml) (NEB) or HSP990 inhibitor (5 mM) (Novartis)
were used. All assays were done in triplicates and repeated at
least three times. Competition assays were performed adding
the purified MEEVD pentapeptide from Biomatik at a final con-
centration of 100 lM to the cell lysates in the 96-well plate.
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Quantification of PDE6a localization
To quantify the relocalization of PDE6a by AIPL1,
pcDNA3.1AXpress-PDE6a was transfected in 8-well chamber
slides in the absence or presence of pCMV-Tag3C-AIPL1 and im-
munocytochemistry performed as described to detect the endog-
enous ER marker BiP (rabbit anti-GRP78/BiP) and PDE6a (anti-
Xpress antibody). The JACoP for ImageJ (41) was used as described
(43) to measure the co-localization of PDE6a with BiP in the cyto-
plasm in the absence and presence of AIPL1. To quantify the ef-
fect of the AIPL1 variants on PDE6a localization, pCMV-Tag3C-
AIPL1 and pcDNA3.1AXpress-PDE6a were co-transfected in 8-well
chamber slides and immunocytochemistry performed as de-
scribed to detect AIPL1 (anti-AIPL1 antibody) and PDE6a (anti-
Xpress antibody). The total number of cells in which PDE6a local-
ized to the ER was counted as a percentage of the total number of
cells expressing PDE6a. Three groups of 50 PDE6a expressing
cells were counted by moving consecutively from one non-
overlapping field to the adjacent contiguous field. The counting
was conducted blind to the identity of the AIPL1 variant co-
transfected and the experiment was repeated at least three times.
To illustrate a deficit in the ability of AIPL1 to redistribute PDE6a
from the ER to the cytosol, the data was transformed as follows:
the reciprocal of the percentage was calculated and multiplied by
100, after which all data was normalized to w/t AIPL1¼ 1. Where
indicated the HSP90 inhibitors HSP990 (Novartis), Geldanamycin
(Selleckchem) and 17-AAG (Selleckchem) were added to the cells
at a concentration of 1lM for 18 h.
PDE6 activity assay
Twenty-four hours post-transfection, cells were lysed in 0.1 N
HCl. Intracellular cGMP concentration was measured using the
competitive cGMP ELISA Kit (Cayman Chemical) following the
manufacturer’s protocols and specifications. The lysates were
acetylated to detect lower concentrations of cGMP. The assay
was done in triplicate and repeated at least three times.
Statistical analysis
Statistical analyses to determine p values for intergroup com-
parisons were conducted using the unpaired Student t-test.
p> 0.01 was considered not significant (NS).
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